Displaying drugs 551 - 575 of 645 in total
Coproporphyrinogen III
Experimental
Matched Iupac: … 5,10,15,19-tetramethyl-21,22,23,24-tetraazapentacyclo[16.2.1.1^{3,6}.1^{8,11}.1^{13,16}]tetracosa-1(20 …
Hydrolyzed soy protein
Experimental
GX-19 Vaccine
The GX-19 vaccine is a DNA vaccine created by Genexine, Inc. Company in Gyeonggi, Korea . As of June 2020, the vaccine candidate is undergoing Phase I and Phase IIa trials to determine dose levels for safety and efficacy[A219758,L16488].
Investigational
Matched Description: … As of June 2020, the vaccine candidate is undergoing Phase I and Phase IIa trials to determine dose levels …
Fimaporfin
Investigational
Pegvorhyaluronidase alfa
Pegvorhyaluronidase alfa is under investigation in clinical trial NCT02241187 (Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection).
Investigational
Matched Synonyms: … HUMAN HYALURONIDASE PH-20 (HYALURONOGLUCOSAMINIDASE PH-20, SPERM ADHESION MOLECULE 1, EC 3.2.1.35) PRECURSOR …
AZD2066
Investigational
Brazikumab
Brazikumab is under investigation in clinical trial NCT03759288 (An Active and Placebo-controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease).
Investigational
COVID-19 Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection
As of July 2020, Medicine Invention Design, Inc. is sponsoring a small, controlled clinical trial for the COVID-19 AP TP Vaccine for ‘proof of concept.’ The vaccine utilizes granulocyte macrophage-colony stimulating factor (GM-CSF), a cytokine known to enhance vaccine efficacy through prolongation of humoral and cell immunity.
Investigational
Matched Description: … As of July 2020, Medicine Invention Design, Inc. is sponsoring a small, controlled clinical trial for …
Pristimerin
Pristimerin is a quinone methide triterpenoid researched for its anti-cancer potential.
Investigational
Matched Synonyms: … .,20.alpha.)- ... .,20.alpha.)-3-hydroxy-9,13-dimethyl-2-oxo-24,25,26-trinoroleana-1(10),3,5,7-tetraen-29-oic acid …
2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a
2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a is under investigation in clinical trial NCT01668823 (Photodynamic Therapy in Treating Patients With Lung Cancer).
Investigational
Matched Synonyms: … 3-PHORBINEPROPANOIC ACID, 14-ETHYL-9-(1-(HEXYLOXY)ETHYL)-4,8,13,18-TETRAMETHYL-20-OXO-, (3S,4S)- …
ZYCOV-D
The ZYCOV-D vaccine candidate was developed by Cadila Healthcare Ltd. based in India . The vaccine was developed using a DNA vaccine platform with a non-replicating and non-integrating plasmid carrying the gene of interest . Once the plasmid DNA is introduced into host cells and the viral protein is translated,...
Investigational
Matched Description: … As of August, 2020 the candidate is in Phase II clinical trials[A219758]. ... Phase I clinical trials of this vaccine candidate were completed in July 2020, with the company reporting …
Gam-COVID-Vac
Gam-COVID-Vac was created by Gamaleya Research Institute of Epidemiology and MIcrobiology in Russia. The vaccine candidate is a heterologous COVID-19 vaccine containing two components, recombinant adenovirus type 26 (rAd26) vector and recombinant adenovirus type 5 (rAd5) vector which both carry the SARS-CoV-2 spike glycoprotein. The vaccine is offered in both...
Investigational
Matched Description: … , and were completed in early August 2020. ... Gam-COVID-Vac;NCT04436471) and freeze-dried (Gam-COVID-Vac Lyo;NCT04437875) vaccine candidates in June 2020 …
20-Hydroxyecdysone
Investigational
Matched Synonyms: … 20-hydroxy-.alpha.-ecdysone …
Matched Name: … 20-Hydroxyecdysone …
Matched Name: … 20-Hydroxyecdysone …
Coronavirus-Like Particle COVID-19 Vaccine
The Coronavirus-Like Particle COVID-19 Vaccine is in development and testing through Meidcago in Quebec City, Canada. The vaccine was developed by creating SARS-Cov-2 virus-like particles (CoVLPs), which mimic the structure of the virus without carrying the genetic components required for infection. VLPs are thought to have multiple mechanisms involving the...
Investigational
Matched Description: … In July 2020, Medicago partnered with Dynavax to test the vaccine with its adjuvant, Cpg 1018 (also known ... A Phase 1 clinical trial was launched in July 2020 evaluating the safety, tolerability, and immunogenicity …
CIGB-258 peptide
CIGB-258 is a peptide that is immunoregulatory and derived from heat shock protein 60 of the cellular variant. As of 2020, The Center for Genetic Engineering and Biotechnology (CIGB) in Havana, Cuba, is testing the treatment efficacy of this peptide in patients with COVID-19 who are under intensive therapy regimens...
Investigational
Matched Description: … As of 2020, The Center for Genetic Engineering and Biotechnology (CIGB) in Havana, Cuba, is testing the …
Redaporfin
Investigational
CVnCoV
The CVnCov Vaccine (or CV07050101) is in development by CureVac AG. The vaccine uses mRNA technology to create a protein associated with SARS-CoV2, and upon administration and replication, to initiate subsequent immune responses in the body. As of June 2020, the company received regulatory approval from German and Belgian Authorities...
Investigational
Matched Description: … As of June 2020, the company received regulatory approval from German and Belgian Authorities to commence …
BNT162b3
The BNT162b3 vaccine is the latest addition to BioNTech and partner Pfizer’s mRNA COVID-19 vaccine program. Similar to BNT162b2, BNT162b3 uses a nucleoside-modified RNA (modRNA) technology. Pfizer and BioNTech deemed this compound as promising in preclinical trials and have decided to initiate further testing of it. As such, BNT162b3 has...
Investigational
Matched Description: … As such, BNT162b3 has entered a phase I/II study in early September 2020 (NCT04537949). …
BBIBP-CorV
BBIBP-CorV vaccine contains a SARS-CoV-2 strain inactivated inside Vero Cells. Investigation shows this vaccine induces neutralizing antibodies in several mammalian species while also showing protective efficacy with SARS-CoV-2 challenge in rhesus macaques . As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials.
Investigational
Matched Description: … As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials …
V591
The V591 vaccine, part of Merck’s COVID-19 vaccine programming, was developed using a modified measles vaccine virus as a vector for COVID-19 antigen delivery . Through Merck’s acquisition of Thermis in May 2020, they were able to leverage Thermis’ platform knowledge and accelerate the development of V591 to phase I...
Investigational
Matched Description: … Through Merck’s acquisition of Thermis in May 2020, they were able to leverage Thermis’ platform knowledge …
K201 free base
Experimental
Investigational
Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences)
The SARS-CoV-2 Inactivated Vaccine is a purified vaccine that contains multiple antigens from the virus and is inactivated in Vero Cells . This vaccine specifically was developed in collaboration with the Chinese Academy of Medical Sciences, West China Second University Hospital, and Yunan Center for Disease Control and Prevention. As...
Investigational
Matched Description: … As of June, 2020, safety and Immunogenicity trials are currently underway for this vaccine (NCT04470609 …
C-CAR039
C-CAR039 is an autologous Chimeric Antigen Receptors (CAR) T-cell therapy expressing CD19/CD20 bi-specific CAR.
Investigational
CVnCoV Vaccine
The CVnCov Vaccine (or CV07050101) is in development by CureVac AG. The vaccine uses mRNA technology to create a protein associated with SARS-CoV2, and upon administration and replication, to initiate subsequent immune responses in the body. As of June 2020, the company received regulatory approval from German and Belgian Authorities...
Investigational
Matched Description: … As of June 2020, the company received regulatory approval from German and Belgian Authorities to commence …
Displaying drugs 551 - 575 of 645 in total